Cargando…
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Drug repurposing is a rapid approach to identifying therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection o...
Autores principales: | Chen, Catherine Z., Shinn, Paul, Itkin, Zina, Eastman, Richard T., Bostwick, Robert, Rasmussen, Lynn, Huang, Ruili, Shen, Min, Hu, Xin, Wilson, Kelli M., Brooks, Brianna, Guo, Hui, Zhao, Tongan, Klump-Thomas, Carleen, Simeonov, Anton, Michael, Samuel G., Lo, Donald C., Hall, Matthew D., Zheng, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444282/ https://www.ncbi.nlm.nih.gov/pubmed/32839771 http://dx.doi.org/10.1101/2020.08.18.255877 |
Ejemplares similares
-
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2021) -
The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators
por: Gorshkov, Kirill, et al.
Publicado: (2020) -
The SARS-CoV-2 Cytopathic Effect Is Blocked
by Lysosome Alkalizing Small Molecules
por: Gorshkov, Kirill, et al.
Publicado: (2020) -
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
por: Hanson, Quinlin M., et al.
Publicado: (2020) -
Targeting ACE2–RBD Interaction as a Platform
for COVID-19 Therapeutics: Development and Drug-Repurposing Screen
of an AlphaLISA Proximity Assay
por: Hanson, Quinlin M., et al.
Publicado: (2020)